The Other Side of the AI Medical Revolution: Health Disparity In recent years, artificial intelligence (AI) has emerged as a leader in innovation within the medical field. AI-powered diagnostic systems have aided in the early detection of fatal diseases like cancer and heart disease, drastically accelerated drug development, and enabled personalized treatment plans for patients. AlphaFold, developed by Google's DeepMind, has shortened drug development periods from years to months by predicting protein structures, while IBM's Watson for Oncology has assisted medical professionals in formulating cancer treatment plans, enhancing accuracy. These technologies go beyond mere medical advancement, opening up new treatment possibilities previously unimaginable. However, behind these dazzling technological achievements lies a critical issue that we must not overlook. This is the 'accessibility gap caused by AI medical technology.' MIT Technology Review recently highlighted the paradoxical reality of rapidly growing AI medical technology worldwide in an analytical article. The concern is that while AI-based technologies expand possibilities, they are simultaneously deepening the healthcare accessibility gap between high-income and low-income countries, and even among different socioeconomic strata within the same nation. The article warned that "AI medical technology could either be a tool for healthcare democratization in the 21st century or the greatest source of inequality," pointing out the adverse effects of technology's benefits remaining out of reach for disadvantaged groups. According to a 2025 report by the World Health Organization (WHO), approximately 87% of global investment in AI medical technology is concentrated in North America and Europe, with Africa and South Asia accounting for only 2% of the total. So, how might this issue affect the Korean healthcare environment? Firstly, the proliferation of AI medical technology heavily depends on the cost of technology adoption. Advanced AI technologies entail substantial initial costs, such as supercomputers, cloud infrastructure, and data collection systems. According to MIT's analysis, introducing a single AI-based medical imaging diagnostic system requires an average initial investment of $500,000 to $2 million (approximately 600 million to 2.5 billion Korean Won), with annual maintenance costs amounting to 15-20% of the initial investment. While developed countries can relatively quickly absorb these costs, allowing AI-driven medical innovation to take root, the situation is different for low-income and developing countries. MIT's analysis shows that the adoption rate of medical AI in high-income countries is approximately 2.8 times higher than in low-income countries, leading to a disparity not just in technology but in healthcare outcomes. This suggests that AI development itself is centered around the economic interests of high-income countries, ultimately exacerbating healthcare inequality. Looking at Korea's situation, the disparity in medical resources between the Seoul metropolitan area and non-metropolitan regions can be seen as a significant example exhibiting a similar pattern. According to the Ministry of Health and Welfare's 2025 survey on medical resources, 72% of all tertiary hospitals nationwide are concentrated in the Seoul-Gyeonggi area, and the adoption rate of AI-based medical equipment is 3.2 times higher in the metropolitan area than in other regions. Professor Kim Min-soo of Seoul National University's Department of Healthcare Management emphasized, "As AI medical technology is primarily introduced in large hospitals, the healthcare gap between regions is widening," adding, "Strategic allocation policies at the government level are necessary." Secondly, even if AI technology becomes widely established in the medical field, there's a high probability that its benefits will not be evenly distributed to all patients. Even within Korea, some high-cost AI-based treatments and diagnostic methods may be more accessible to certain socioeconomic groups with better financial means. For instance, while AI-based genetic analysis services are useful for certain cancer treatments, the cost to be borne by the patient can be a significant burden if not covered by national health insurance. AI-based precision medicine packages offered by major domestic hospitals range from 3 million to 10 million Korean Won in patient co-payments, an amount exceeding the average monthly income of a middle-class household. Korea's Healthcare System and the Future of AI According to 2025 data from the Health Insurance Review and Assessment Service (HIRA), only 23% of AI-based diagnostic and treatment technologies are covered by national health insurance benefits, with the remainder falling under non-covered or elective treatment categories. This implies the potential for additional burdens on lower and middle-income groups. Professor Park Ji-young of Yonsei University'
Related Articles